OBJECTIVE Cabergoline is now established as an effective and well-tolerated treatment for prolactinoma. However, there are relatively few published data on the treatment of macro-, as opposed to micro-, prolactinoma. We have therefore reviewed the efficacy and safety of cabergoline in the treatment of patients with prolactin-secreting macroadenomas treated on a compassionate basis. STUDY DESIGN AND PATIENTS Eighty-five patients with prolactin-secreting macroadenomas were treated with cabergoline 0 . 25 to 10 . 5 mg per week (median 1 mg) given in one to seven doses. Treatment durations ranged between 3 months and 8 years. Sixty-five patients (32 intolerant, 16 resistant) had been treated previously with other dopamine agonists.Pretreatment prolactin levels ranged between 80 and 8300 mg/l and tumour maximum diameters were between 11 and 42 mm. MEASUREMENTS Serum prolactin, visual fields if initially abnormal, occurrence of menses or return of libido and potency, blood chemistry and adverse events were assessed at 1 month and then at 3-

ABSTRACT

No abstract

No abstract

No abstract